1
|
Lai K, Sun D, Dai R, Samoro R, Park HS, Åstrand A, Cohen D, Jison M, Shih VH, Werkström V, Yao Y, Zhang Y, Zheng W, Zhong N, Albert A, Jianping B, Bi C, Lijun C, Mei C, Min C, Ping C, Zhimin C, Chih-Feng C, Sook CY, Xiuhua F, Xiwen G, Wei G, Wei H, Zhihai H, Wei HX, Kewu H, Mao H, Grace Dawn IM, Inbeom J, Luning J, Mingyan J, Shanping J, Meiling J, Jian K, Woo KJ, Sang-Ha K, Jiulong K, Ping-Hung K, Jie L, Manxiang L, Minjing L, Ruoran L, Wen L, Xianhua L, Yanming L, Yong LS, Chuanhe L, Chuntao L, Jing L, Xiaoxia L, Huiyu L, Zhuang L, Shengxi M, Liangping M, Hoon MK, Lin M, Choon-Sik P, Sim PH, Hye-Kyung P, Jung-Won P, Diahn-Warng P, Ronnie S, Guochao S, Debin S, Dejun S, Chun-Hua W, Guangfa W, Limin W, Xuefen W, Yan W, Liping W, Haihong W, Yi X, Zuke X, Canmao X, Jin-Fu X, Xingxiang X, Xiyuan X, Jianping Y, Hongzhong Y, Joo YH, Wencheng Y, Jin Z, Longju Z, Min Z, Wei Z, Jianping Z, Ziwen Z, Xiaoli Z, Yingqun Z. Benralizumab efficacy and safety in severe asthma: A randomized trial in Asia. Respir Med 2024:107611. [PMID: 38570145 DOI: 10.1016/j.rmed.2024.107611] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/12/2024] [Revised: 03/19/2024] [Accepted: 03/24/2024] [Indexed: 04/05/2024]
Abstract
BACKGROUND Benralizumab is indicated as add-on therapy in patients with uncontrolled, severe eosinophilic asthma; it has not yet been evaluated in a large Asian population with asthma in a clinical trial. OBJECTIVE To evaluate the efficacy and safety of benralizumab in patients with severe asthma in Asia. METHODS MIRACLE (NCT03186209) was a randomized, Phase 3 study in China, South Korea, and the Philippines. Patients aged 12-75 years with severe asthma receiving medium-to-high-dose inhaled corticosteroid/long-acting β2-agonists, stratified (2:1) by baseline blood eosinophil count (bEOS) (≥300/μL; <300/μL), were randomized (1:1) to benralizumab 30 mg or placebo. Endpoints included annual asthma exacerbation rate (AAER; primary endpoint), change from baseline at Week 48 in pre-bronchodilator (BD) forced expiratory volume in 1 second (pre-BD FEV1) and total asthma symptom score (TASS). Safety was evaluated ≤ Week 56. RESULTS Of 695 patients randomized, 473 had baseline bEOS ≥300/μL (benralizumab n = 236; placebo n = 237). In this population, benralizumab significantly reduced AAER by 74% (rate ratio 0.26 [95% CI 0.19, 0.36], p < 0.0001) and significantly improved pre-BD FEV1 (least squares difference [LSD] 0.25 L [95% CI 0.17, 0.34], p < 0.0001) and TASS (LSD -0.25 [-0.45, -0.05], p = 0.0126) versus placebo. In patients with baseline bEOS <300/μL, there were numerical improvements in AAER, pre-BD FEV1, and TASS with benralizumab versus placebo. The frequency of adverse events was similar for benralizumab (76%) and placebo (80%) in the overall population. CONCLUSIONS MIRACLE data reinforces the efficacy and safety of benralizumab for severe eosinophilic asthma in an Asian population, consistent with the global Phase 3 results.
Collapse
Affiliation(s)
- Kefang Lai
- Guangzhou Institute of Respiratory Health, State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, National Center for Respiratory Medicine, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China
| | - Dejun Sun
- Inner Mongolia People's Hospital, Hohhot, China
| | - Ranran Dai
- Ruijin Hospital Shanghai Jiao Tong University School of Medicine, Shanghai, China
| | - Ronnie Samoro
- Healthlink Medical-Surgical-Dental Clinics and Diagnostic Center, Iloilo City, Philippines
| | - Hae-Sim Park
- Ajou University School of Medicine, Ajou University Medical Center, Suwon, Republic of Korea
| | - Annika Åstrand
- Late-stage Respiratory & Immunology, AstraZeneca, Gothenburg, Sweden
| | - David Cohen
- Late-stage Respiratory & Immunology, AstraZeneca, Gaithersburg, MD, USA
| | - Maria Jison
- Late-stage Respiratory & Immunology, AstraZeneca, Gaithersburg, MD, USA
| | - Vivian H Shih
- BioPharmaceuticals Medical, AstraZeneca, Gaithersburg, MD, USA
| | | | - Yuhui Yao
- Respiratory & Immunology, R&D China, AstraZeneca, Shanghai, China
| | - Yajuan Zhang
- Respiratory & Immunology, R&D China, AstraZeneca, Shanghai, China
| | | | - Nanshan Zhong
- Guangzhou Institute of Respiratory Health, State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, National Center for Respiratory Medicine, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.
| | - Albay Albert
- Manila Doctors Hospital, Metro Manila, Philippines
| | - Bo Jianping
- Second Hospital of Shanxi Medical University, Shanxi, China
| | - Chen Bi
- The Affiliated Hospital of Xuzhou Medical University, Xuzhou, China
| | - Chen Lijun
- Yinchuan First People's Hospital, Yinchuan, China
| | - Chen Mei
- Chengdu Fifth People's Hospital, Sichuan, China
| | - Chen Min
- The Affiliated Hospital of Guangdong Medical University, Zhanjiang, China
| | - Chen Ping
- The General Hospital of Shenyang Military, Shenyang, China
| | - Chen Zhimin
- The Children's Hospital of Zhejiang University College of Medicine, Zhejiang, China
| | | | | | - Fu Xiuhua
- The Affiliated Hospital of Inner Mongolia Medical University, Hohhot, China
| | - Gao Xiwen
- Central Hospital of Minhang District, Shanghai, China
| | - Gu Wei
- Nanjing First Hospital, Nanjing, China
| | - Han Wei
- Qingdao Municipal Hospital, Qingdao, China
| | | | - Hu Xi Wei
- The Affiliated Hospital of Guizhou Medical University, Guizhou, China
| | - Huang Kewu
- Beijing Chaoyang Hospital, Beijing, China
| | - Huang Mao
- Jiangsu Province Hospital, Jiangsu, China
| | | | - Jeong Inbeom
- Konyang University Hospital, Daejeon, Republic of Korea
| | - Jiang Luning
- Affiliated Hospital of Jining Medical College, Jining, China
| | | | - Jiang Shanping
- Sun Yat-Sen Memorial Hospital Sun Yat-Sen University, Guangzhou, China
| | - Jin Meiling
- Zhongshan Hospital of Fudan University, Shangha, China
| | - Kang Jian
- The First Affiliated Hospital of China Medical University, Chongqing, China
| | - Kim Jin Woo
- The Catholic University of Korea, Seoul, Republic of Korea
| | - Kim Sang-Ha
- Yonsei University Wonju Severance Christian Hospital, Gangwon-do, Republic of Korea
| | - Kuang Jiulong
- The Second Affiliated Hospital of Nanchang University, Nanchang, China
| | | | - Li Jie
- First Affiliated Hospital of Ganzhou Medical University, Guangzhou, China
| | - Li Manxiang
- The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China
| | - Li Minjing
- The First People's Hospital of Foshan, Foshan, China
| | - Li Ruoran
- Xuzhou Central Hospital, Jiangsu, China
| | - Li Wen
- The Second Affiliated Hospital of Zhejiang University School of Medicine, Zhejiang, China
| | - Li Xianhua
- The First People's Hospital of Neijiang, Neijiang, China
| | | | | | - Liu Chuanhe
- Children's Hospital, Capital Institute of Pediatrics, Beijing, China
| | - Liu Chuntao
- West China Hospital, Sichuan University, Sichuan, China
| | - Liu Jing
- The Fifth Affiliated Hospital Sun YAT-SEN University, China
| | | | - Lu Huiyu
- Taizhou People's Hospital, Taizhou, China
| | - Luo Zhuang
- First Affiliated Hospital of Kunming Medical University, Kunming, China
| | - Ma Shengxi
- Xinxiang Central Hospital, Xinxiang, China
| | - Mao Liangping
- Chongqing Three Gorges Central Hospital, Chongqing, China
| | - Min Kyung Hoon
- Korea University Guro Hospital, Seoul, Republic of Korea
| | - Mu Lin
- Heping Hospital Affiliated to Changzhi Medical College, Changzhi, China
| | - Park Choon-Sik
- Soonchunhyang University Bucheon Hospital, Bucheon, Republic of Korea
| | - Park Hae Sim
- Ajou University Hospital, Suwon-si, Republic of Korea
| | - Park Hye-Kyung
- Pusan National University Hospital, Busan, Republic of Korea
| | | | | | - Samoro Ronnie
- Healthlink Medical-Surgical-Dental Clinics and Diagnostic Center, Iloilo City, Philippines
| | - Shi Guochao
- Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
| | - Sun Debin
- Lishui Central Hospital, Lishui, China
| | - Sun Dejun
- Inner Mongolia People's Hospital, Hohhot, China
| | - Wang Chun-Hua
- Linkou Chang Gung Memorial Hospital, Taoyuan, Taiwan
| | - Wang Guangfa
- Peking University First Hospital, Beijing, China
| | - Wang Limin
- Hangzhou First People's Hospital, Hangzhou, China
| | - Wang Xuefen
- The First Affiliated Hospital Zhejiang University, Zhejiang, China
| | - Wang Yan
- The Second Affiliated Hospital of Army Medical University, PLA, China
| | - Wei Liping
- The Third Affiliated Hospital of Guangzhou Medical University, Guangzhou, China
| | | | - Xiao Yi
- Yanan Hospital, Kunming City, Yunnan, China
| | - Xiao Zuke
- Jiangxi Provincial People's Hospital, Jiangxi, China
| | - Xie Canmao
- The First Affiliated Hospital of Sun Yat-Sen University, Guangzhou, China
| | - Xu Jin-Fu
- Shanghai Pulmonary Hospital, Shanghai, China
| | - Xu Xingxiang
- Northern Jiangsu People's Hospital, Jiangsu, China
| | - Xu Xiyuan
- The First Affiliated Hospital of Baotou Medical College, Inner Mongolia, China
| | - Yan Jianping
- Zhejiang Provincial People's Hospital, Zhejiang, China
| | | | - Yoon Ho Joo
- Hanyang University Seoul Hospital, Seoul, Republic of Korea
| | - Yu Wencheng
- The Affiliated Hospital of Qingdao University, Qingdao, China
| | - Zhang Jin
- General Hospital of Ningxia Medical University, Yinchuan, China
| | - Zhang Longju
- The First People's Hospital of Zunyi, Zunyi, China
| | - Zhang Min
- The People's Hospital of Ganzhou, Ganzhou, China
| | - Zhang Wei
- The First Affiliated Hospital of Nanchang University, Nanchang, China
| | - Zhao Jianping
- Tongji Hospital of Huazhong Science and Technology University, Wuhan, China
| | - Zhao Ziwen
- Guangzhou First People's Hospital, Guangzhou, China
| | - Zhu Xiaoli
- Zhongda Hospital Southeast University, Nanjing, China
| | - Zhu Yingqun
- The Third Hospital of Changsha, Changsha, China
| |
Collapse
|
3
|
Yuyun D, Zhihua T, Haijun W, Zhaoping L, Xiaoli Z, Wenfang X, Faxiang J, Hongmei L. Predictive value of the red blood cell distribution width-to-platelet ratio for hepatic fibrosis. Scand J Gastroenterol 2019; 54:81-86. [PMID: 30663454 DOI: 10.1080/00365521.2018.1558786] [Citation(s) in RCA: 13] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/04/2023]
Abstract
AIMS The red blood cell distribution width-to-platelet ratio (RPR) has been reported to be an indicator of hepatic fibrosis in patients with chronic hepatitis B (HBV), nonalcoholic fatty liver disease (NAFLD) or chronic hepatitis C (HCV). However, no research has explored the RPR in all patients with hepatic fibrosis. There is a recognized need to establish whether the RPR could assess hepatic fibrosis and reflect the severity of fibrosis, regardless of the patient's etiology. METHODS Quantitative data from 1282 patients who underwent liver biopsy between January 2010 and December 2014 at the Second Affiliated Hospital of Zhejiang University School of Medicine were included. The etiologies included HBV or HCV infection, NAFLD, schistosomiasis, granulomatous liver disease, and vascular abnormalities. Five noninvasive models were calculated for all patients based on laboratory parameters. The degrees of fibrosis severity were evaluated based on the Metavir scoring scale. RESULTS The RPR demonstrated the best accuracy of predicting hepatic fibrosis among the selected five models (0.75, p < .001) regardless of etiology. In addition, the RPR values increased with advanced hepatic fibrosis progression. Furthermore, combining the RPR with the white blood cell (WBC) count improved the accuracy of grading hepatic fibrosis as reflected by the likelihood ratio (LR + 9.03, LR - 0.49). CONCLUSION The RPR is a useful indicator for hepatic fibrosis, regardless of etiology, and can reflect the severity of fibrosis. This study supports further clinical development of the RPR both in a stepwise manner or in combination with inflammatory parameters to improve the accuracy of scoring hepatic fibrosis.
Collapse
Affiliation(s)
- Ding Yuyun
- a Department of Laboratory Medicine , The Affiliated Hospital of Shaoxing University , Shaoxing , China
| | - Tao Zhihua
- b Department of Laboratory Medicine , The Second Affiliated Hospital of Zhejiang University School of Medicine Laboratory Medicine , Hangzhou , China
| | - Wang Haijun
- c Department of Pathology , The Second Affiliated Hospital of Zhejiang University School of Medicine , Hangzhou , China
| | - Liao Zhaoping
- d Department of Blood transfusion , The Second Affiliated Hospital of Zhejiang University School of Medicine , Hangzhou , China
| | - Zhu Xiaoli
- e Department of Laboratory Medicine , Taizhou Hospital of Zhejiang Province , Linhai City , China
| | - Xu Wenfang
- f Department of Laboratory Medicine , The Affiliated Hospital of Shaoxing University , Shaoxing , China
| | - Jin Faxiang
- f Department of Laboratory Medicine , The Affiliated Hospital of Shaoxing University , Shaoxing , China
| | - Liu Hongmei
- f Department of Laboratory Medicine , The Affiliated Hospital of Shaoxing University , Shaoxing , China
| |
Collapse
|